Anti-Human DLL3 Recombinant Antibody

Product Information

Catalog Number	YR1386
Product Name	Anti-Human DLL3 Recombinant Antibody
Molecular Name	Rovalpituzumab
Alias	Anti-DLL3 Recombinant Antibody, Research Grade Rovalpituzumab
CAS Number	1613313-01-1
Target	DLL3[Homo sapiens]
Isotype	IgG1 Kappa
Clonity	Monoclonal
Source	CHO Cells
Size	1mg, 5mg
Concentration	1mg/ml
Purity	>95% as determined by SDS-PAGE
Buffer	PBS, pH7.5
Background	Rovalpituzumab tesirine (Rova-T) is an experimental antibody-drug conjugate targeting the protein DLL3 on tumor cells. It was originally developed by Stemcentrx and was purchased by AbbVie. It was tested for use in small-cell lung cancer, but development was terminated after unsuccessful phase III trial.
Storage	It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles.
Note	This product is for research use only.

Cat#	Product Name	Species	Host	Applications	Size	Price